These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18246521)

  • 1. Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases.
    Dadachova E; Casadevall A
    Curr Opin Investig Drugs; 2008 Feb; 9(2):184-8. PubMed ID: 18246521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases.
    Dadachova E; Casadevall A
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1075-84. PubMed ID: 16296810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming antibodies for cancer therapy.
    Polakis P
    Curr Opin Pharmacol; 2005 Aug; 5(4):382-7. PubMed ID: 15951239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the development and manufacturing of antibody-drug conjugates.
    Ducry L
    Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of infection with radiolabeled antibodies.
    Dadachova E; Casadevall A
    Q J Nucl Med Mol Imaging; 2006 Sep; 50(3):193-204. PubMed ID: 16868533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
    Dosio F; Brusa P; Cattel L
    Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive antibody therapy for infectious diseases.
    Casadevall A; Dadachova E; Pirofski LA
    Nat Rev Microbiol; 2004 Sep; 2(9):695-703. PubMed ID: 15372080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody-drug conjugates and their application in the treatment of hematological malignancies].
    Lin L; Ding Q; Tang Q; Zhang ZZ; Dai Z; Zhan JB
    Yao Xue Xue Bao; 2012 Oct; 47(10):1287-96. PubMed ID: 23289140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based immunotherapy in high-risk neuroblastoma.
    Johnson E; Dean SM; Sondel PM
    Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and untoward toxicities of antibody-based immunoconjugates.
    Litvak-Greenfeld D; Benhar I
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1782-99. PubMed ID: 22659123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of antibodies in the treatment of infectious diseases.
    Chan CE; Chan AH; Hanson BJ; Ooi EE
    Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using antibodies to target cancer therapeutics.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2012 Sep; 12(9):1173-90. PubMed ID: 22650606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arming antibodies: prospects and challenges for immunoconjugates.
    Wu AM; Senter PD
    Nat Biotechnol; 2005 Sep; 23(9):1137-46. PubMed ID: 16151407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.